XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
 9 Months Ended
Sep. 30, 2024
Concentration Risk And Geographic Information [Abstract]  
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
The Company operates in one business segment, which focuses on the development and commercialization of innovative therapies for patients with serious and life-threatening rare diseases and medical conditions.
The following table presents Total Revenues and disaggregates Net Product Revenues by product.
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
VOXZOGO$189,785 $122,973 $526,597 $324,146 
VIMIZIM178,158 158,869 548,694 525,453 
NAGLAZYME131,906 108,916 369,584 322,040 
PALYNZIQ90,634 78,885 254,634 216,105 
ALDURAZYME71,029 13,812 144,849 88,533 
BRINEURA37,005 41,042 121,361 118,244 
KUVAN28,115 42,947 92,576 144,047 
ROCTAVIAN7,235 822 15,516 822 
Total net product revenues733,867 568,266 2,073,811 1,739,390 
Royalty and other revenues11,873 13,063 32,791 33,629 
Total revenues$745,740 $581,329 $2,106,602 $1,773,019 
The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide.
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
United States$235,515 $194,745 $655,963 $553,184 
Europe191,017 168,784 607,755 512,910 
Latin America111,908 81,524 274,920 224,716 
Rest of world124,398 109,401 390,324 360,047 
Total net product revenues marketed by the Company$662,838 $554,454 $1,928,962 $1,650,857 
ALDURAZYME net product revenues marketed by Sanofi71,029 13,812 144,849 88,533 
Total net product revenues$733,867 $568,266 $2,073,811 $1,739,390 
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Customer A12 %13 %11 %12 %
Customer B11 15 13 15 
Customer C10 10 10 10 
Total33 %38 %34 %37 %
On a consolidated basis, one customer accounted for 18% of the Company’s September 30, 2024 accounts receivable balance compared to December 31, 2023, when two customers accounted for 15% and 12% of the accounts receivable balance, respectively. As of September 30, 2024, and December 31, 2023, the accounts receivable balance for Sanofi included $94.2 million and $63.4 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances.
The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, geopolitical instability, and supply chain disruptions, could affect the Company’s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.